原发性膜性肾病复发危险因素的研究进展
Research Progress on Risk Factors for the Recurrence of Primary Membranous Nephropathy
DOI: 10.12677/acm.2026.1682946, PDF,   
作者: 邓嘉炜, 汤显湖*：赣南医科大学第一临床医学院，江西 赣州
关键词: 原发性膜性肾病；复发；危险因素；综述；Primary Membranous Nephropathy； Recurrence； Risk Factors； Review
摘要: 原发性膜性肾病(primary membranous nephropathy, PMN)是一种以肾小球基底膜上皮细胞下沉积免疫复合物以及基底膜弥漫性增厚为特点的肾小球疾病，是成人肾病综合征最常见的原因，虽然有些病人经过治疗可以达到临床治愈，但是仍然有一部分患者会再次出现病情复发的情况，这严重影响了病人的预后以及生活质量。本文全面系统地分析了原发性膜性肾病复发的各种危险因素，包括遗传学因素、免疫因素、治疗因素、临床因素以及环境和生活行为因素等方面，对各种因素的研究现状和具体机制进行了详细的论述，旨在为临床预防和治疗原发性膜性肾病复发提供一个较为完整的参考依据，从而促进相关领域的进一步研究和发展，改善患者的临床结局。
Abstract: Primary membranous nephropathy (PMN) is a glomerular disease characterized by subepithelial deposition of immune complexes in the glomerular basement membrane and diffuse thickening of the basement membrane. It is the most common cause of nephrotic syndrome in adults. Although some patients can achieve clinical cure after treatment, some still experience recurrence, which seriously affects patients’ prognosis and quality of life. From multiple perspectives, this article comprehensively and systematically analyzes various risk factors for the recurrence of primary membranous nephropathy, including genetic factors, immune factors, therapeutic factors, clinical factors, as well as environmental and lifestyle factors. It provides a detailed discussion on the research status and specific mechanisms of these factors, aiming to offer a comprehensive reference for clinical prevention and treatment of primary membranous nephropathy recurrence, thereby promoting further research and development in related fields and improving patients’ clinical outcomes.
文章引用：邓嘉炜, 汤显湖. 原发性膜性肾病复发危险因素的研究进展[J]. 临床医学进展, 2026, 16(8): 1650-1658. https://doi.org/10.12677/acm.2026.1682946

参考文献

[1] Stanescu, H.C., Arcos-Burgos, M., Medlar, A., Bockenhauer, D., Kottgen, A., Dragomirescu, L., et al. (2011) Risk HLA-DQA1 and PLA2R1 Alleles in Idiopathic Membranous Nephropathy. New England Journal of Medicine, 364, 616-626.
https://doi.org/10.1056/nejmoa1009742
[2] Qin, X.S., Liu, J.H., Lyu, G.T., Peng, M., Yang, F., Qin, D., et al. (2017) Variants in the Promoter Region of HLA-DQA1 Were Associated with Idiopathic Membranous Nephropathy in a Chinese Han Population. Chinese Medical Journal, 130, 1677-1682.
https://doi.org/10.4103/0366-6999.209884
[3] Bullich, G., Ballarín, J., Oliver, A., Ayasreh, N., Silva, I., Santín, S., et al. (2014) HLA-DQA1 and PLA2R1 Polymorphisms and Risk of Idiopathic Membranous Nephropathy. Clinical Journal of the American Society of Nephrology, 9, 335-343.
https://doi.org/10.2215/cjn.05310513
[4] Ramachandran, R., Kumar, V., Kumar, A., Yadav, A.K., Nada, R., Kumar, H., et al. (2015) PLA2R Antibodies, Glomerular PLA2R Deposits and Variations in PLA2R1 and HLA-DQA1 Genes in Primary Membranous Nephropathy in South Asians. Nephrology Dialysis Transplantation, 31, 1486-1493.
https://doi.org/10.1093/ndt/gfv399
[5] Berchtold, L., Letouzé, E., Alexander, M.P., Canaud, G., Logt, A.v.d., Hamilton, P., et al. (2021) HLA-D and PLA2R1 Risk Alleles Associate with Recurrent Primary Membranous Nephropathy in Kidney Transplant Recipients. Kidney International, 99, 671-685.
https://doi.org/10.1016/j.kint.2020.08.007
[6] Beck, L.H., Bonegio, R.G.B., Lambeau, G., Beck, D.M., Powell, D.W., Cummins, T.D., et al. (2009) M-Type Phospholipase A2 Receptor as Target Antigen in Idiopathic Membranous Nephropathy. New England Journal of Medicine, 361, 11-21.
https://doi.org/10.1056/nejmoa0810457
[7] Cui, Z., Xie, L., Chen, F., Pei, Z., Zhang, L., Qu, Z., et al. (2017) MHC Class II Risk Alleles and Amino Acid Residues in Idiopathic Membranous Nephropathy. Journal of the American Society of Nephrology, 28, 1651-1664.
https://doi.org/10.1681/asn.2016020114
[8] Hofstra, J.M., Beck, L.H., Beck, D.M., Wetzels, J.F. and Salant, D.J. (2011) Anti-Phospholipase A2 Receptor Antibodies Correlate with Clinical Status in Idiopathic Membranous Nephropathy. Clinical Journal of the American Society of Nephrology, 6, 1286-1291.
https://doi.org/10.2215/cjn.07210810
[9] Ruggenenti, P., Debiec, H., Ruggiero, B., Chianca, A., Pellé, T., Gaspari, F., et al. (2015) Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy. Journal of the American Society of Nephrology, 26, 2545-2558.
https://doi.org/10.1681/asn.2014070640
[10] Beck, L.H., Fervenza, F.C., Beck, D.M., Bonegio, R.G.B., Malik, F.A., Erickson, S.B., et al. (2011) Rituximab-Induced Depletion of Anti-PLA2R Autoantibodies Predicts Response in Membranous Nephropathy. Journal of the American Society of Nephrology, 22, 1543-1550.
https://doi.org/10.1681/asn.2010111125
[11] 饶思捷. PLA2R抗体与特发性膜性肾病临床特征和不良结局的关联: 一项荟萃分析[D]: [硕士学位论文]. 重庆: 重庆医科大学, 2022.
[12] 潘鸿魁. 原发性膜性肾病复发危险因素分析[D]: [硕士学位论文]. 南宁: 广西医科大学, 2022.
[13] Tomas, N.M., Beck, L.H., Meyer-Schwesinger, C., Seitz-Polski, B., Ma, H., Zahner, G., et al. (2014) Thrombospondin Type-1 Domain-Containing 7A in Idiopathic Membranous Nephropathy. New England Journal of Medicine, 371, 2277-2287.
https://doi.org/10.1056/nejmoa1409354
[14] Iwakura, T., Ohashi, N., Kato, A., Baba, S. and Yasuda, H. (2015) Prevalence of Enhanced Granular Expression of Thrombospondin Type-1 Domain-Containing 7A in the Glomeruli of Japanese Patients with Idiopathic Membranous Nephropathy. PLOS ONE, 10, e0138841.
https://doi.org/10.1371/journal.pone.0138841
[15] Hoxha, E., Beck, L.H., Wiech, T., Tomas, N.M., Probst, C., Mindorf, S., et al. (2017) An Indirect Immunofluorescence Method Facilitates Detection of Thrombospondin Type 1 Domain-Containing 7A-Specific Antibodies in Membranous Nephropathy. Journal of the American Society of Nephrology, 28, 520-531.
https://doi.org/10.1681/asn.2016010050
[16] Zaghrini, S., Tufano, A., Gini, B., et al. (2023) Development of a Novel ELISA to Detect Anti-THSD7A Antibodies in Membranous Nephropathy. Clinica Chimica Acta, 537, 246-252.
[17] Huang, C.C., Lehman, A., Albawardi, A., Satoskar, A., Brodsky, S., Nadasdy, G., et al. (2013) IgG Subclass Staining in Renal Biopsies with Membranous Glomerulonephritis Indicates Subclass Switch during Disease Progression. Modern Pathology, 26, 799-805.
https://doi.org/10.1038/modpathol.2012.237
[18] 计蕾, 余慰, 钟雪. 特发性膜性肾病患者血清抗磷脂酶A2受体抗体与尿中IgG4检测的临床意义[J]. 中国免疫学杂志, 2018, 34(7): 1050-1055.
[19] 黄雯静, 孟晓燕. 特发性膜性肾病患者血清抗磷脂酶A2受体抗体与尿中IgG4的检测价值[J]. 人人健康, 2019(24): 251-252.
[20] Cravedi, P., Ronco, P. and Debiec, H. (2014) Circulating Memory B Cells Secreting Anti-PLA2R Antibodies in Idiopathic Membranous Nephropathy. Journal of the American Society of Nephrology, 25, 1804-1813.
[21] Cremoni, D., Pasquali, S., Ravani, P., et al. (2011) Th17 and Th2 Cytokines in Membranous Nephropathy: Association with Disease Activity and Urban Environment. Clinical Journal of the American Society of Nephrology, 6, 1923-1930.
[22] Chen, R.-J., et al. (2022) Comparative Efficacy of Three Regimens (Cyclosporine, Tacrolimus, and Cyclophosphamide) Combined with Steroids for the Treatment of Idiopathic Membranous Nephropathy. Nefrología, 42, 671-679.
https://doi.org/10.1016/j.nefro.2021.08.006
[23] Praga, M., Barrio, V., Juárez, G.F. and Luño, J. (2007) Tacrolimus Monotherapy in Membranous Nephropathy: A Randomized Controlled Trial. Kidney International, 71, 924-930.
https://doi.org/10.1038/sj.ki.5002215
[24] Di, J., Qian, Q., Yang, M., Jiang, Y., Zhou, H., Li, M., et al. (2018) Efficacy and Safety of Long-Course Tacrolimus Treatment for Idiopathic Membranous Nephropathy. Experimental and Therapeutic Medicine, 16, 979-984.
https://doi.org/10.3892/etm.2018.6211
[25] Liang, S., Liang, Y., Li, Z., Wang, Y., Guo, X., Zhang, C., et al. (2023) Evaluating Efficacy and Safety of Tacrolimus Treatment in Membranous Nephropathy: Results of a Retrospective Study of 182 Patients. Therapeutics and Clinical Risk Management, 19, 351-360.
https://doi.org/10.2147/tcrm.s399218
[26] 袁卓杰. 特发性膜性肾病复发危险因素分析[D]: [硕士学位论文]. 广州: 广州中医药大学, 2020.
[27] Ponticelli, C., Zucchelli, P., Passerini, P., Cesana, B., Locatelli, F., Pasquali, S., et al. (1995) A 10-Year Follow-Up of a Randomized Study with Methylprednisolone and Chlorambucil in Membranous Nephropathy. Kidney International, 48, 1600-1604.
https://doi.org/10.1038/ki.1995.453
[28] Jha, V., Ganguli, A., Saha, T.K., Kohli, H.S., Sud, K., Gupta, K.L., et al. (2007) A Randomized, Controlled Trial of Steroids and Cyclophosphamide in Adults with Nephrotic Syndrome Caused by Idiopathic Membranous Nephropathy. Journal of the American Society of Nephrology, 18, 1899-1904.
https://doi.org/10.1681/asn.2007020166
[29] van den Brand, J.A.J.G., Ruggenenti, P., Chianca, A., Hofstra, J.M., Perna, A., Ruggiero, B., et al. (2017) Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy. Journal of the American Society of Nephrology, 28, 2729-2737.
https://doi.org/10.1681/asn.2016091022
[30] van den Brand, J.A.J.G., van Dijk, P.R., Hofstra, J.M. and Wetzels, J.F.M. (2014) Cancer Risk after Cyclophosphamide Treatment in Idiopathic Membranous Nephropathy. Clinical Journal of the American Society of Nephrology, 9, 1066-1073.
https://doi.org/10.2215/cjn.08880813
[31] Trujillo, H., Alonso, M. and Praga, M. (2020) New Ways of Understanding Membranous Nephropathy. Nephron, 144, 261-271.
https://doi.org/10.1159/000506948
[32] Huang, L., Dong, Q., Zhao, Y. and Hu, G. (2021) Rituximab for the Management of Idiopathic Membranous Nephropathy: A Meta-Analysis. International Urology and Nephrology, 53, 111-119.
https://doi.org/10.1007/s11255-020-02633-5
[33] Gauckler, P., Shin, J.I., Alberici, F., Audard, V., Bruchfeld, A., Busch, M., et al. (2021) Rituximab in Membranous Nephropathy. Kidney International Reports, 6, 881-893.
https://doi.org/10.1016/j.ekir.2020.12.035
[34] Boyer-Suavet, S., Andreani, M., Lateb, M., Savenkoff, B., Brglez, V., Benzaken, S., et al. (2020) Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated with Rituximab. Frontiers in Immunology, 10, Article No. 3069.
https://doi.org/10.3389/fimmu.2019.03069
[35] 肖沐阳. 利妥昔单抗治疗特发性膜性肾病的临床分析[D]: [硕士学位论文]. 扬州: 扬州大学, 2024.
[36] 冯琳鸿, 王亚琨, 吴茜茜, 等. 利妥昔单抗治疗成人难治性原发性膜性肾病的临床分析[J]. 上海交通大学学报(医学版), 2023, 43(3): 301-307.
[37] Li, Z., Zhao, T., Zhang, S., Huang, J., Wang, H., Sun, Y., et al. (2024) Efficacy Analysis of Rituximab in Treating Patients with Primary Membranous Nephropathy Dependent on Calcineurin Inhibitors. Frontiers in Immunology, 15, Article ID: 1504646.
https://doi.org/10.3389/fimmu.2024.1504646
[38] Xu, X., Wang, G., Chen, N., Lu, T., Nie, S., Xu, G., et al. (2016) Long-Term Exposure to Air Pollution and Increased Risk of Membranous Nephropathy in China. Journal of the American Society of Nephrology, 27, 3739-3746.
https://doi.org/10.1681/asn.2016010093
[39] Cremoni, M., Brglez, V., Perez, S., Decoupigny, F., Zorzi, K., Andreani, M., et al. (2020) Th17-Immune Response in Patients with Membranous Nephropathy Is Associated with Thrombosis and Relapses. Frontiers in Immunology, 11, Article ID: 574997.
https://doi.org/10.3389/fimmu.2020.574997
[40] 岑雅伶. 膜性肾病治疗后复发的多因素分析[D]: [硕士学位论文]. 南宁: 广西医科大学, 2020.

为你推荐